Supply Chain entity
All 1 tracked stories fall under one category: manufacturing. AbbVie is most often covered alongside Eli Lilly, which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 3 original sources each against 2.7 for the same window.
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: manufacturing. AbbVie is most often covered alongside Eli Lilly, which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 3 original sources each against 2.7 for the same window. Their average consequence score of 7 runs above the beat's 6.2 for that window. We currently track 1 Supply Chain story that mention AbbVie, all published on February 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 32 Supply Chain stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AbbVie. Shared-story counts are live from our verified record — not editorial picks.
Operational Launch
The new facilities are expected to come online and begin API production.
Construction Start
Anticipated groundbreaking for the two new manufacturing plants.
Manufacturing Expansion
AbbVie announces $380 million investment for North Chicago API facilities.
$100B Pledge
AbbVie commits to $100 billion in U.S. R&D and capital investments over the next decade.
AbbVie has announced a $380 million investment to expand active pharmaceutical ingredient (API) manufacturing in North Chicago, marking the first major step in a $100 billion decade-long commitment to U.S. R&D and production. The move aligns with federal efforts to reshore critical drug supply chains and lower costs through direct-to-patient channels like TrumpRx.
AbbVie is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
